ONS ONCC CHEMOTHERAPY IMMUNOTHERAPY
EVALUATION 2026 QUESTIONS AND ANSWERS
SURE A+
✔✔Pulmonary fibrosis is possible when the lifetime dose of bleomycin exceeds: -
✔✔400 units
✔✔What 6 patient characteristics make CINV more likely? - ✔✔1. Younger than 50
years
2. Hx of low alcohol intake
3. Female gender
4. Hx of morning sickness during pregnancy
5. Prone to motion sickness
6. Previous chemotherapy
✔✔Types of CINV: - ✔✔Acute
Delayed
Breakthrough
Anticipatory
Refractory
✔✔Define acute CINV - ✔✔Occurring within 24 hours of chemotherapy
✔✔Define delayed CINV - ✔✔Occurring from 24 hours to 5 days after treatment
✔✔Define breakthrough CINV - ✔✔Occurring despite treatment
✔✔Define anticipatory CINV - ✔✔Triggered by taste, odor, memories, visions, or
anxiety related to chemotherapy
✔✔Define refractory CINV - ✔✔Occurring during subsequent cycles when treatment
failed in earlier cycles
, ✔✔Moderately emetogenic chemo (MEC) causes CINV in patients ___% to ___% of the
time - ✔✔30-90
✔✔Patients on low-potential emetogenic chemo develop CINV ___% to ___% of the
time - ✔✔10-30
✔✔Minimal-risk emetogenic chemo causes CINV less than ___% of the time - ✔✔10
✔✔Common IV HEC drugs include: - ✔✔Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Mechlorethamine
Streptozosin
✔✔Common IV MEC drugs include: - ✔✔Carboplatin
Cytarabine
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin
✔✔Common low-potential IV emetogenic chemo drugs include: - ✔✔5-FU
Cytarabine
Docetaxel
Etoposide
Gemcitabine
Methotrexate
Mitomycin C
Mitoxantrone
Paclitaxel
Pemetrexed
✔✔Common minimal-risk IV emetogenic chemo drugs include: - ✔✔Bleomycin
Bevacizumab
Bortezomib
Busulfan
Cetuximab
Fludarabine
Trastuzumab
Vinca alkaloids
EVALUATION 2026 QUESTIONS AND ANSWERS
SURE A+
✔✔Pulmonary fibrosis is possible when the lifetime dose of bleomycin exceeds: -
✔✔400 units
✔✔What 6 patient characteristics make CINV more likely? - ✔✔1. Younger than 50
years
2. Hx of low alcohol intake
3. Female gender
4. Hx of morning sickness during pregnancy
5. Prone to motion sickness
6. Previous chemotherapy
✔✔Types of CINV: - ✔✔Acute
Delayed
Breakthrough
Anticipatory
Refractory
✔✔Define acute CINV - ✔✔Occurring within 24 hours of chemotherapy
✔✔Define delayed CINV - ✔✔Occurring from 24 hours to 5 days after treatment
✔✔Define breakthrough CINV - ✔✔Occurring despite treatment
✔✔Define anticipatory CINV - ✔✔Triggered by taste, odor, memories, visions, or
anxiety related to chemotherapy
✔✔Define refractory CINV - ✔✔Occurring during subsequent cycles when treatment
failed in earlier cycles
, ✔✔Moderately emetogenic chemo (MEC) causes CINV in patients ___% to ___% of the
time - ✔✔30-90
✔✔Patients on low-potential emetogenic chemo develop CINV ___% to ___% of the
time - ✔✔10-30
✔✔Minimal-risk emetogenic chemo causes CINV less than ___% of the time - ✔✔10
✔✔Common IV HEC drugs include: - ✔✔Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Mechlorethamine
Streptozosin
✔✔Common IV MEC drugs include: - ✔✔Carboplatin
Cytarabine
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Oxaliplatin
✔✔Common low-potential IV emetogenic chemo drugs include: - ✔✔5-FU
Cytarabine
Docetaxel
Etoposide
Gemcitabine
Methotrexate
Mitomycin C
Mitoxantrone
Paclitaxel
Pemetrexed
✔✔Common minimal-risk IV emetogenic chemo drugs include: - ✔✔Bleomycin
Bevacizumab
Bortezomib
Busulfan
Cetuximab
Fludarabine
Trastuzumab
Vinca alkaloids
